Cover Image
Market Research Report
Product code 
1022276

Cellular Immunotherapy Market Report 2021-2031: Forecasts by Therapy Type, by Products & Services, by Testing Assays Type, by Indication, Regional & Leading National Market Analysis, Leading Companies, COVID-19 Recovery Scenarios

Published: | Visiongain Ltd | 461 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cellular Immunotherapy Market Report 2021-2031: Forecasts by Therapy Type, by Products & Services, by Testing Assays Type, by Indication, Regional & Leading National Market Analysis, Leading Companies, COVID-19 Recovery Scenarios
Published: June 8, 2021
Visiongain Ltd
Content info: 461 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Title:
Cellular Immunotherapy Market Report 2021-2031
Forecasts by Therapy Type (CAR-T Cell Therapy, NK Cell Therapy, TIL Therapy, Others), by Products & Services (Cellular Immunotherapy Products, Cellular Immunotherapy Services), by Testing Assays Type (Bioanalytics, Characterization, Biosafety), by Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cellular Immunotherapy Companies AND COVID-19 Recovery Scenarios.

Global Cellular Immunotherapy Market Outlook

According to Visiongain analysis, global cellular immunotherapy market was valued at US$xx billion in 2020 and is expected to grow at a CAGR of xx% during the forecast period 2021-2031 to reach US$xx billion by 2031.

Key Questions Answered by this Report:

  • What is the current size of the overall global cellular immunotherapy market? How much will this market be worth from 2021 to 2031?
  • What are the main drivers and restraints that will shape the overall cellular immunotherapy market over the next ten years?
  • What are the main segments within the overall cellular immunotherapy market?
  • How much will each of these segments be worth for the period 2021 to 2031?
  • How will the composition of the market change during that time, and why?
  • What factors will affect that industry and market over the next ten years?
  • What are the largest national markets for the world cellular immunotherapy?
  • What is their current status and how will they develop over the next ten years?
  • What are their revenue potentials to 2031?
  • How will political and regulatory forces influence regional markets?
  • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are the leading cellular immunotherapy? What are their revenues and latest developments?
  • What are some of the most prominent cellular immunotherapy currently in development?
  • What are the main trends that will affect the world cellular immunotherapy market between 2021 and 2031?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that industry over the next ten years?
  • How will the global cellular immunotherapy market evolve over the forecasted period, 2021 to 2031?
  • What will be the main commercial drivers for the market from 2021 to 2031?
  • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2021 and 2031, especially in R&D?

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Rising demand for advanced therapies for cancer treatment is boosting the growth of global market. Find out why.

Immunotherapy, along with chemotherapy, surgery, and radiotherapy, has started to emerge as the "fourth pillar" of treatment for cancer in the last decade. Immunotherapy has transformed cancer treatment and revitalized tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have produced long-term clinical responses in cancer patients. The initial focus of CAR-T-cell therapies was primarily on ALL, the most common childhood cancer. The Food and Drug Administration (FDA) approved two CAR-T-cell therapies in 2017, one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.

Discover sales predictions for the global cellular immunotherapy market and submarkets

Over the last few years, cellular immunotherapy has gained widespread attention due to its high efficiency and adoption for the treatment of patients with severe cancer. Along with revenue prediction for the overall world market, there are 4 segmentations of the Cellular Immunotherapy market, with forecasts for 4 Therapy Type, 2 Products & Services, 3 Testing Assay Types, each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Who are the leading players analysed in the market?

  • Novartis AG
  • Gilead Sciences, Inc.
  • Adicet Bio
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Iovance Biotherapeutics, Inc.
  • Tessa Therapeutics Ltd.
  • Inovio Pharmaceuticals, Inc.
  • AstraZeneca
  • Adaptimmune Therapeutics plc.
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • APAC Biotech
  • JW shinyak (JW CreaGene)

Buy our report today“ Cellular Immunotherapy Market Report 2021-2031: Forecasts by Therapy Type (CAR-T Cell Therapy, NK Cell Therapy, TIL Therapy, Others), by Products & Services (Cellular Immunotherapy Products, Cellular Immunotherapy Services), by Testing Assays Type (Bioanalytics, Characterization, Biosafety), by Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cellular Immunotherapy Companies AND COVID-19 Recovery Scenarios. ” Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents
Product Code: PHA1123

Table of Contents

1. Report Overview

  • 1.1 Introduction to Cellular Immunotherapy Market
  • 1.2 Why You Should Read This Report
  • 1.3 What This Report Delivers
  • 1.4 Key Questions Answered By This Analytical Report Include:
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
    • 1.6.3 Market Evaluation & Forecast Methodology
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2 Executive Summary

3 Market Dynamics

  • 3.1 Drivers for Cellular Immunotherapy Market
    • 3.1.1 Increasing Prevalence of Cancer is driving the Market
    • 3.1.2 Increasing Geriatric Population around the World is Boosting the Demand for Cellular Immunotherapy
    • 3.1.3 Development of Advanced Cellular Immunotherapy is Driving the Cellular Immunotherapy Market
    • 3.1.4 Support from National Cancer Institute for Immunotherapy is estimated to propel the Market Growth
  • 3.2 Restraints for Cellular Immunotherapy Market
    • 3.2.1 Stringent Regulations Associated with Product Development Hinders the Market Growth
    • 3.2.2 High Costs of Cellular Immunotherapy Limits the Market Growth
    • 3.2.3 Complex Supply Chain and Manufacturing Could limit the Entry of New Players
  • 3.3 Opportunities for Cellular Immunotherapy Market
    • 3.3.1 Increasing Demand for the Advanced Cellular Immunotherapy for Cancer Treatment Is Projected to Boost the Market Growth
    • 3.3.2 Mergers, Agreements, and Acquisitions by the Market Players is a Major Trend Witnessed in the Market
  • 3.4 Challenges for Cellular Immunotherapy Market
    • 3.4.1 Adverse Effects associated With Cellular Immunotherapy could Limit its Adoption
    • 3.4.2 Reimbursement Issues for the Advanced Cellular Immunotherapy
  • 3.5 SWOT Analysis for Cellular Immunotherapy Market
    • 3.5.1 Strengths: Cellular Immunotherapy Market
      • 3.5.1.1 Rising Popularity of Cellular Immunotherapy for Cancer Treatment
      • 3.5.1.2 Escalating Clinical-research Infrastructure in Asia Pacific Region
    • 3.5.2 Weaknesses: Cellular Immunotherapy Market
      • 3.5.2.1 Complexity of Cellular Immunotherapies
      • 3.5.2.2 Changing Regulatory Requirements
    • 3.5.3 Opportunities: Cellular Immunotherapy Market
      • 3.5.3.1 Increase in Collaborations between Biopharmaceutical Companies and Academic Research Centers
      • 3.5.3.2 Advantages of CAR-T-Therapy for the Treatment of Liquid Tumors
    • 3.5.4 Threats: Cellular Immunotherapy Market
      • 3.5.4.1 Availability of Alternative Treatment Options
      • 3.5.4.2 Ethical Issues Associated with Cellular Immunotherapy
  • 3.6 Porter's Five Forces Analysis: Cellular Immunotherapy Market
    • 3.6.1 Bargaining Power of Supplier: High
    • 3.6.2 Bargaining Power of Buyer: Low
    • 3.6.3 Competitive Rivalry: High
    • 3.6.4 Threat of New Entrants: Moderate
    • 3.6.5 Threat of Substitutes: Low
  • 3.7 PEST Analysis: Cellular Immunotherapy Market
    • 3.7.1 Political Factors Impacting Cellular Immunotherapy Market
    • 3.7.2 Economic Factors Impacting Cellular Immunotherapy Market
    • 3.7.3 Social Factors Impacting Cellular Immunotherapy Market
    • 3.7.4 Technological Factors Impacting Cellular Immunotherapy Market

4 COVID-19 Impact: Global Cellular Immunotherapy Market

  • 4.1 Global Cellular Immunotherapy Market Forecast, 2021-2031
  • 4.2 COVID-19 Impact Overview
  • 4.3 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
  • 4.4 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
  • 4.5 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
  • 4.6 "L" Shaped Recovery - Rapid Decline - Then Slow Growth

5 Global Cellular Immunotherapy Market Size Forecast 2021-2031 by Therapy Type

  • 5.1 Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031
    • 5.1.1 CAR-T Cell Therapy is the Largest Revenue Grossing Segment
    • 5.1.2 Recovery Forecasts (V, U, W, L)
  • 5.2 Global NK (Natural Killer) Cell Therapy Segment: Revenue Forecast 2021-2031
    • 5.2.1 NK Cell Lines Offer a Robust Cytotoxicity against Cancer Cells
    • 5.2.2 Recovery Forecasts (V, U, W, L)
  • 5.3 Global Tumor-Infiltrating Lymphocyte (TIL) Therapy Segment: Revenue Forecast 2021-2031
    • 5.3.1 TIL Therapy is a Promising form of Adoptive Cellular Immunotherapy
    • 5.3.2 Recovery Forecasts (V, U, W, L)
  • 5.4 Global Others Segment: Revenue Forecast 2021-2031
    • 5.4.1 Promising Engineered T-Cell Receptor (TCR) and Dendritic Cell (DC)-based Therapies are expected to boost the Other Cell Therapy Segment Growth
    • 5.4.2 Recovery Forecasts (V, U, W, L)

6 Cellular Immunotherapy Market by Product and Services Forecast, 2021-2031

  • 6.1 Global Cellular Immunotherapy Product Segment Market Forecast, 2021-2031
    • 6.1.1 Cellular Immunotherapy Product Segment is showing the Highest CAGR during the Forecast Period
    • 6.1.2 Recovery Scenarios (V, U, W, L)
  • 6.2 Global Cellular Immunotherapy Services Segment Market Forecast, 2021-2031
    • 6.2.1 Rising Investment in Cell-Based Therapies R&D is driving the Cellular Immunotherapy Services Segment
    • 6.2.2 Recovery Scenarios (V, U, W, L)

7 Cellular Immunotherapy Market by Testing Assays Type Forecast, 2021-2031

  • 7.1 Bioanalytics Segment Market Forecast, 2021-2031
    • 7.1.1 Largest-Revenue Growing Segment in the Market
    • 7.1.2 Recovery Scenarios (V, U, W, L)
  • 7.2 Characterization Segment Market Forecast, 2021-2031
    • 7.2.1 Second-Largest Revenue Generating Segment
    • 7.2.2 Recovery Scenarios (V, U, W, L)
  • 7.3 Biosafety Segment Market Forecast, 2021-2031
    • 7.3.1 Well-defined Regulations for the Cellular Therapies in the Developed Countries Is Expected To Drive the Market Growth
    • 7.3.2 Recovery Scenarios (V, U, W, L)

8 Global Cellular Immunotherapy Market Size Forecast 2021-2031 by Indication

  • 8.1 Global B-cell Malignancies Segment: Revenue Forecast 2021-2031
    • 8.1.1 B-cell Malignancies is the Largest Revenue Grossing Segment
    • 8.1.2 Recovery Forecasts (V, U, W, L)
  • 8.2 Global Prostate Cancer Segment: Revenue Forecast 2021-2031
    • 8.2.1 sipuleucel-T (Provenge) has been Approved by the US FDA for the Treatment of Prostate Cancer
    • 8.2.2 Recovery Forecasts (V, U, W, L)
  • 8.3 Global Liver Cancer Segment: Revenue Forecast 2021-2031
    • 8.3.1 Liver Cancer Segment is Expected to Grow at a Lucrative Growth Rate
    • 8.3.2 Recovery Forecasts (V, U, W, L)
  • 8.4 Global Renal Cell Carcinoma Segment: Revenue Forecast 2021-2031
    • 8.4.1 Growing Investment in Cellular Immunotherapy for the Treatment of Renal Cell Carcinoma is projected to Drive the Segment Growth
    • 8.4.2 Recovery Forecasts (V, U, W, L)
  • 8.5 Global Others Segment: Revenue Forecast 2021-2031
    • 8.5.1 Growing Demand for Advanced Drugs Is Expected to Propel the Others Segment Growth
    • 8.5.2 Recovery Forecasts (V, U, W, L)

9 National Cellular Immunotherapy Market Forecast, 2021-2031

  • 9.1 Global Cellular Immunotherapy Market by Region Forecast 2021-2031
  • 9.1 Recovery Scenarios (V, U, W, L)

10 North America Cellular Immunotherapy Market, 2021-2031

  • 10.1 North America is the Largest Revenue Grossing Region in the Global Market
  • 10.2 North America Cellular Immunotherapy Market by Country, Forecast 2021-2031
  • 10.3 North America Cellular Immunotherapy Market Forecast by Therapy Type
  • 10.4 North America Cellular Immunotherapy Market Forecast by Product & Service
  • 10.5 North America Cellular Immunotherapy Market Forecast by Testing Assays Type
  • 10.6 North America Cellular Immunotherapy Market Forecast by Indication
  • 10.7 Recovery Scenarios (V, U, W, L): North America Market
    • 10.7.1 V-Shaped Recovery
      • 10.7.1.1 North America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 10.7.1.2 North America Cellular Immunotherapy Market Forecast by Therapy Type
      • 10.7.1.3 North America Cellular Immunotherapy Market Forecast by Product & Service
      • 10.7.1.4 North America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 10.7.1.5 North America Cellular Immunotherapy Market Forecast by Indication
    • 10.7.2 U-Shaped Recovery
      • 10.7.2.1 North America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 10.7.2.2 North America Cellular Immunotherapy Market Forecast by Therapy Type
      • 10.7.2.3 North America Cellular Immunotherapy Market Forecast by Product & Service
      • 10.7.2.4 North America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 10.7.2.5 North America Cellular Immunotherapy Market Forecast by Indication
    • 10.7.3 W-Shaped Recovery
      • 10.7.3.1 North America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 10.7.3.2 North America Cellular Immunotherapy Market Forecast by Therapy Type
      • 10.7.3.3 North America Cellular Immunotherapy Market Forecast by Product & Service
      • 10.7.3.4 North America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 10.7.3.5 North America Cellular Immunotherapy Market Forecast by Indication
    • 10.7.4 L-Shaped Recovery
      • 10.7.4.1 North America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 10.7.4.2 North America Cellular Immunotherapy Market Forecast by Therapy Type
      • 10.7.4.3 North America Cellular Immunotherapy Market Forecast by Product & Service
      • 10.7.4.4 North America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 10.7.4.5 North America Cellular Immunotherapy Market Forecast by Indication
  • 10.8 U.S. Cellular Immunotherapy Market Forecast, 2021-2031
    • 10.8.1 Presence of Leading Players is a Major factor driving the U.S. Cellular Imunotherapy Market
    • 10.8.2 Presence of Highly Developed Healthcare Infrastructure
  • 10.9 Canada Cellular Immunotherapy Market Forecast, 2021-2031
    • 10.9.1 Canada Market Anticipated To Witness the Fastest Growth in the North America Region
    • 10.9.2 Growing Canadian research collaborations determined to Provide Infrastructure for Cell-Based Therapy Research

11 Europe Cellular Immunotherapy Market, 2021-2031

  • 11.1 Second Largest Market in the Global Market
  • 11.2 Europe Cellular Immunotherapy Market by Country, Forecast 2021-2031
  • 11.3 Europe Cellular Immunotherapy Market Forecast by Therapy Type
  • 11.4 Europe Cellular Immunotherapy Market Forecast by Product & Service
  • 11.5 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type
  • 11.6 Europe Cellular Immunotherapy Market Forecast by Indication
  • 11.7 Recovery Scenarios (V, U, W, L): Europe Market
    • 11.7.1 V-Shaped Recovery
      • 11.7.1.1 Europe Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 11.7.1.2 Europe Cellular Immunotherapy Market Forecast by Therapy Type
      • 11.7.1.3 Europe Cellular Immunotherapy Market Forecast by Product & Service
      • 11.7.1.4 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 11.7.1.5 Europe Cellular Immunotherapy Market Forecast by Indication
    • 11.7.2 U-Shaped Recovery
      • 11.7.2.1 Europe Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 11.7.2.2 Europe Cellular Immunotherapy Market Forecast by Therapy Type
      • 11.7.2.3 Europe Cellular Immunotherapy Market Forecast by Product & Service
      • 11.7.2.4 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 11.7.2.5 Europe Cellular Immunotherapy Market Forecast by Indication
    • 11.7.3 W-Shaped Recovery
      • 11.7.3.1 Europe Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 11.7.3.2 Europe Cellular Immunotherapy Market Forecast by Therapy Type
      • 11.7.3.3 Europe Cellular Immunotherapy Market Forecast by Product & Service
      • 11.7.3.4 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 11.7.3.5 Europe Cellular Immunotherapy Market Forecast by Indication
    • 11.7.4 L-Shaped Recovery
      • 11.7.4.1 Europe Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 11.7.4.2 Europe Cellular Immunotherapy Market Forecast by Therapy Type
      • 11.7.4.3 Europe Cellular Immunotherapy Market Forecast by Product & Service
      • 11.7.4.4 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 11.7.4.5 Europe Cellular Immunotherapy Market Forecast by Indication
  • 11.8 Germany Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.8.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
    • 11.8.2 Rising Focus on CAR-T Cell and NK Cell Therapies R&D in Germany
  • 11.9 UK Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.9.1 Presence of Well-Developed R&D Infrastructure
    • 11.9.2 Rise in Number of Treatment Centers in the UK
  • 11.10 France Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.10.1 Growing Demand for Advanced Healthcare Services
    • 11.10.2 Rising Preference for France for Cellular Therapy R&D and Manufacturing by Leading Players
  • 11.11 Italy Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.11.1 Pharmaceutical Manufacturing Hub
    • 11.11.2 Growing Acceptance of Cellular Therapies for the Treatment of Cancer in Italy is projected to drive the Market Growth
  • 11.12 Spain Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.12.1 Demand for Drugs Is Influenced By the Growth of the Pharmaceutical Industry
    • 11.12.2 Spanish Economy Is Growing Strong
  • 11.13 Russia Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.13.1 Growing Government Support for the Development of Advanced Cancer Therapies
    • 11.13.2 Unmet Pharmaceutical Needs
  • 11.14 Rest of Europe Cellular Immunotherapy Market Forecast, 2021-2031
    • 11.14.1 Increasing Prevalence of Cancer

12 Asia Pacific Cellular Immunotherapy Market, 2021-2031

  • 12.1 Asia Pacific is the Fastest Growing Market
  • 12.2 Asia Pacific Cellular Immunotherapy Market by Country, Forecast 2021-2031
  • 12.3 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type
  • 12.4 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service
  • 12.5 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type
  • 12.6 Asia Pacific Cellular Immunotherapy Market Forecast by Indication
  • 12.7 Recovery Scenarios (V, U, W, L): APAC Market
    • 12.7.1 V-Shaped Recovery
      • 12.7.1.1 Asia Pacific Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 12.7.1.2 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type
      • 12.7.1.3 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service
      • 12.7.1.4 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 12.7.1.5 Asia Pacific Cellular Immunotherapy Market Forecast by Indication
    • 12.7.2 U-Shaped Recovery
      • 12.7.2.1 Asia Pacific Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 12.7.2.2 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type
      • 12.7.2.3 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service
      • 12.7.2.4 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 12.7.2.5 Asia Pacific Cellular Immunotherapy Market Forecast by Indication
    • 12.7.3 W-Shaped Recovery
      • 12.7.3.1 Asia Pacific Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 12.7.3.2 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type
      • 12.7.3.3 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service
      • 12.7.3.4 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 12.7.3.5 Asia Pacific Cellular Immunotherapy Market Forecast by Indication
    • 12.7.4 L-Shaped Recovery
      • 12.7.4.1 Asia Pacific Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 12.7.4.2 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type
      • 12.7.4.3 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service
      • 12.7.4.4 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 12.7.4.5 Asia Pacific Cellular Immunotherapy Market Forecast by Indication
  • 12.8 Japan Cellular Immunotherapy Market Forecast, 2021-2031
    • 12.8.1 Japan Accounted For the Largest Market Share in the Asia Pacific Region
    • 12.8.2 Rising Number of Product Approval is Expected to Drive the Market Growth
  • 12.9 China Cellular Immunotherapy Market Forecast, 2021-2031
    • 12.9.1 Strategic Initiatives Undertaken by the Market Players
    • 12.9.2 Increasing Healthcare Spending In China
  • 12.10 India Cellular Immunotherapy Market Forecast, 2021-2031
    • 12.10.1 Developing Healthcare Infrastructure
    • 12.10.2 Increasing Prevalence of Cancer
  • 12.11 Australia Cellular Immunotherapy Market Forecast, 2021-2031
    • 12.11.1 Government Programs to Expand Access to Quality Healthcare
    • 12.11.2 Launch of Cell-based Therapies in Australia is Projected to Boost the Market Growth
  • 12.12 South Korea Cellular Immunotherapy Market Forecast, 2021-2031
    • 12.12.1 Growing Healthcare Awareness among People
    • 12.12.2 Rising Cancer Incidence is Expected to Drive theSouth Korea Market
  • 12.13 Rest of Asia Pacific Cellular Immunotherapy Market Forecast, 2021-2031
    • 12.13.1 Rising Disposable Income

13 Latin America Cellular Immunotherapy Market, 2021-2031

  • 13.1 Latin America Cellular Immunotherapy Market
  • 13.2 Latin America Cellular Immunotherapy Market by Country, Forecast 2021-2031
  • 13.3 Latin America Cellular Immunotherapy Market Forecast by Therapy Type
  • 13.4 Latin America Cellular Immunotherapy Market Forecast by Product & Service
  • 13.5 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type
  • 13.6 Latin America Cellular Immunotherapy Market Forecast by Indication
  • 13.7 Recovery Scenarios (V, U, W, L): Latin America Market
    • 13.7.1 V-Shaped Recovery
      • 13.7.1.1 Latin America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 13.7.1.2 Latin America Cellular Immunotherapy Market Forecast by Therapy Type
      • 13.7.1.3 Latin America Cellular Immunotherapy Market Forecast by Product & Service
      • 13.7.1.4 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 13.7.1.5 Latin America Cellular Immunotherapy Market Forecast by Indication
    • 13.7.2 U-Shaped Recovery
      • 13.7.2.1 Latin America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 13.7.2.2 Latin America Cellular Immunotherapy Market Forecast by Therapy Type
      • 13.7.2.3 Latin America Cellular Immunotherapy Market Forecast by Product & Service
      • 13.7.2.4 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 13.7.2.5 Latin America Cellular Immunotherapy Market Forecast by Indication
    • 13.7.3 W-Shaped Recovery
      • 13.7.3.1 Latin America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 13.7.3.2 Latin America Cellular Immunotherapy Market Forecast by Therapy Type
      • 13.7.3.3 Latin America Cellular Immunotherapy Market Forecast by Product & Service
      • 13.7.3.4 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 13.7.3.5 Latin America Cellular Immunotherapy Market Forecast by Indication
    • 13.7.4 L-Shaped Recovery
      • 13.7.4.1 Latin America Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 13.7.4.2 Latin America Cellular Immunotherapy Market Forecast by Therapy Type
      • 13.7.4.3 Latin America Cellular Immunotherapy Market Forecast by Product & Service
      • 13.7.4.4 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 13.7.4.5 Latin America Cellular Immunotherapy Market Forecast by Indication
  • 13.8 Brazil Cellular Immunotherapy Market Forecast, 2021-2031
    • 13.8.1 Fastest Growing Economy in Latin America
    • 13.8.2 High Potential Manufacturing Environment
  • 13.9 Mexico Cellular Immunotherapy Market Forecast, 2021-2031
    • 13.9.1 Lower Manufacturing Costs than In the US
    • 13.9.2 Strategic Initiatives Undertaken By Market Players
  • 13.10 Rest of Latin America Cellular Immunotherapy Market Forecast, 2021-2031
    • 13.10.1 Evolving Healthcare Infrastructure in Latin America

14 MEA Cellular Immunotherapy Market, 2021-2031

  • 14.1 Rising Prevalence of Cancer in MEA Region
  • 14.2 MEA Cellular Immunotherapy Market by Country, Forecast 2021-2031
  • 14.3 MEA Cellular Immunotherapy Market Forecast by Therapy Type
  • 14.4 MEA Cellular Immunotherapy Market Forecast by Product & Service
  • 14.5 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type
  • 14.6 MEA Cellular Immunotherapy Market Forecast by Indication
  • 14.7 Recovery Scenarios (V, U, W, L): MEA Market
    • 14.7.1 V-Shaped Recovery
      • 14.7.1.1 MEA Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 14.7.1.2 MEA Cellular Immunotherapy Market Forecast by Therapy Type
      • 14.7.1.3 MEA Cellular Immunotherapy Market Forecast by Product & Service
      • 14.7.1.4 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 14.7.1.5 MEA Cellular Immunotherapy Market Forecast by Indication
    • 14.7.2 U-Shaped Recovery
      • 14.7.2.1 MEA Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 14.7.2.2 MEA Cellular Immunotherapy Market Forecast by Therapy Type
      • 14.7.2.3 MEA Cellular Immunotherapy Market Forecast by Product & Service
      • 14.7.2.4 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 14.7.2.5 MEA Cellular Immunotherapy Market Forecast by Indication
    • 14.7.3 W-Shaped Recovery
      • 14.7.3.1 MEA Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 14.7.3.2 MEA Cellular Immunotherapy Market Forecast by Therapy Type
      • 14.7.3.3 MEA Cellular Immunotherapy Market Forecast by Product & Service
      • 14.7.3.4 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 14.7.3.5 MEA Cellular Immunotherapy Market Forecast by Indication
    • 14.7.4 L-Shaped Recovery
      • 14.7.4.1 MEA Cellular Immunotherapy Market by Country, Forecast 2021-2031
      • 14.7.4.2 MEA Cellular Immunotherapy Market Forecast by Therapy Type
      • 14.7.4.3 MEA Cellular Immunotherapy Market Forecast by Product & Service
      • 14.7.4.4 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type
      • 14.7.4.5 MEA Cellular Immunotherapy Market Forecast by Indication
  • 14.8 South Africa Cellular Immunotherapy Market Forecast, 2021-2031
    • 14.8.1 Prevalence of Cancer in South Africa is Increasing Rapidly
    • 14.8.2 Population Exposed to Mining Suffers from Cancer
  • 14.9 GCC Cellular Immunotherapy Market Forecast, 2021-2031
    • 14.9.1 Presence of Huge Growth Opportunities
    • 14.9.2 Advances in personalised medicine and immuno-oncology have ushered in a paradigm change
  • 14.10 Rest of MEA Cellular Immunotherapy Market Forecast, 2021-2031
    • 14.10.1 Cancer Is One of the Leading Causes of Death
    • 14.10.2 Extensive Tobacco Use Increases Incidence of Cancer

15 Company Profiles: Cellular Immunotherapy Market

  • 15.1 Cellular Immunotherapy Market: Company Share Analysis
  • 15.2 Cellular Immunotherapy Market Recent Developments, 2017-2021
  • 15.3 Novartis AG
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2016-2020
      • 15.3.3.2 Business Segments Revenue Shares, 2020
      • 15.3.3.3 Pharmaceuticals Business Unit Revenue Shares, 2020
      • 15.3.3.4 Regional Revenue Shares, 2020
    • 15.3.4 Product Benchmarking
    • 15.3.5 Recent Developments, 2017-2021
  • 15.4 Gilead Sciences, Inc.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2016-2020
      • 15.4.3.2 Business Segments Revenue Shares, 2020
      • 15.4.3.3 Regional Revenue Shares, 2020
    • 15.4.4 Product Benchmarking
    • 15.4.5 Recent Developments, 2017-2021
  • 15.5 Adicet Bio
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2016-2020
    • 15.5.4 Product Benchmarking
    • 15.5.5 Recent Developments, 2018-2021
  • 15.6 GlaxoSmithKline plc.
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Revenue, 2016-2020
      • 15.6.3.2 Pharmaceutical Business Revenue Share, 2020
      • 15.6.3.3 Regional Revenue Shares, 2020
    • 15.6.4 Product Benchmarking
    • 15.6.5 Recent Developments, 2018-2021
  • 15.7 Pfizer Inc.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2016-2020
      • 15.7.3.2 Product Revenue Shares, 2020
      • 15.7.3.3 Regional Revenue Shares, 2020
    • 15.7.4 Product Benchmarking
    • 15.7.5 Recent Developments, 2018-2021
  • 15.8 F. Hoffmann-La Roche Ltd.
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2016-2020
      • 15.8.3.2 Product Revenue Shares, 2020
      • 15.8.3.3 Regional Revenue Shares, 2020
    • 15.8.4 Product Benchmarking
    • 15.8.5 Recent Developments, 2018-2021
  • 15.9 Iovance Biotherapeutics, Inc.
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Recent Developments, 2018-2021
  • 15.10 Tessa Therapeutics Ltd.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Product Benchmarking
    • 15.10.4 Recent Developments, 2018-2021
  • 15.11 Inovio Pharmaceuticals, Inc.
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2016-2020
    • 15.11.4 Product Benchmarking
    • 15.11.5 Recent Developments, 2018-2021
  • 15.12 AstraZeneca
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2016-2020
      • 15.12.3.2 Product Revenue Shares, 2020
      • 15.12.3.3 Regional Revenue Shares, 2020
    • 15.12.4 Product Benchmarking
    • 15.12.5 Recent Developments, 2018-2021
  • 15.13 Adaptimmune Therapeutics plc.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2016-2020
    • 15.13.4 Product Benchmarking
  • 15.14 Atara Biotherapeutics, Inc.
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Product Benchmarking
    • 15.14.4 Recent Developments, 2018-2021
  • 15.15 Bristol-Myers Squibb Company
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2016-2020
      • 15.15.3.2 Regional Revenue Shares, 2020
    • 15.15.4 Product Benchmarking
    • 15.15.5 Recent Developments, 2018-2021
  • 15.16 APAC Biotech
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Product Benchmarking
  • 15.17 JW shinyak (JW CreaGene)
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Product Benchmarking
    • 15.17.4 Recent Developments, 2018-2021

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
  • 16.3 Leading Regions and Fastest Growing Region (North America Region Accounted

List of Tables

  • Table 1 Global Cellular Immunotherapy Market, 2020 & 2031 (US$ bn, CAGR %)
  • Table 2 Worldwide Cancer Incidence, 2020
  • Table 3 Global Cellular Immunotherapy Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
  • Table 4 Global Cellular Immunotherapy Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
  • Table 5 Global Cellular Immunotherapy Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
  • Table 6 Global Cellular Immunotherapy Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
  • Table 7 Global Cellular Immunotherapy Market Size Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
  • Table 8 Global Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 9 Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 10 "V" Shaped Recovery: Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 11 "U" Shaped Recovery: Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 12 "W" Shaped Recovery: Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 13 "L" Shaped Recovery: Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 14 Global NK Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 15 "V" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 16 "U" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 17 "W" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 18 "L" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 19 Global TIL Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 20 "V" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 21 "U" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 22 "W" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 23 "L" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 24 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 25 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 26 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 27 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 28 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 29 Global Cellular Immunotherapy Market Forecast by Product and Services, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 30 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 31 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 32 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 33 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 34 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 35 Global Cellular Immunotherapy Market for Services Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 36 Global Cellular Immunotherapy Market for Services Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 37 Global Cellular Immunotherapy Market for Services Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 38 Global Cellular Immunotherapy Market for Services Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 39 Global Cellular Immunotherapy Market for Services Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 40 Global Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 41 Global Cellular Immunotherapy Market for Bioanalytics Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 42 Global Cellular Immunotherapy Market for Bioanalytics Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 43 Global Cellular Immunotherapy Market for Bioanalytics Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 44 Global Cellular Immunotherapy Market for Bioanalytics Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 45 Global Cellular Immunotherapy Market for Bioanalytics Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 46 Global Cellular Immunotherapy Market for Characterization Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 47 Global Cellular Immunotherapy Market for Characterization Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 48 Global Cellular Immunotherapy Market for Characterization Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 49 Global Cellular Immunotherapy Market for Characterization Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 50 Global Cellular Immunotherapy Market for Characterization Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 51 Global Cellular Immunotherapy Market for Biosafety Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 52 Global Cellular Immunotherapy Market for Biosafety Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 53 Global Cellular Immunotherapy Market for Biosafety Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 54 Global Cellular Immunotherapy Market for Biosafety Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 55 Global Cellular Immunotherapy Market for Biosafety Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 56 Global Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 57 Global B-cell Malignancies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 58 "V" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 59 "U" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 60 "W" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 61 "L" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 62 Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 63 "V" Shaped Recovery: Global B-cell malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 64 "U" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 65 "W" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 66 "L" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 67 Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR %)
  • Table 68 "V" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 69 "U" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 70 "W" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 71 "L" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 72 Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 73 "V" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 74 "U" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 75 "W" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 76 "L" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 77 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 78 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 79 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 80 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 81 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%, CAGR%)
  • Table 82 Global Cellular Immunotherapy Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 83 Global Cellular Immunotherapy Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 84 Global Cellular Immunotherapy Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 85 Global Cellular Immunotherapy Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 86 Global Cellular Immunotherapy Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
  • Table 87 North America Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 88 North America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 89 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 90 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 91 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 92 North America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 93 North America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 94 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 95 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 96 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 97 North America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 98 North America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 99 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 100 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 101 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 102 North America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 103 North America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 104 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 105 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 106 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 107 North America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 108 North America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 109 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 110 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 111 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 112 North America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 113 U.S. Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 114 Canada Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 115 Europe Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 116 Europe Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 117 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 118 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 119 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 120 Europe Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 121 Europe Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 122 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 123 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 124 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 125 Europe Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 126 Europe Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 127 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 128 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 129 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 130 Europe Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 131 Europe Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 132 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 133 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 134 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 135 Europe Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 136 Europe Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 137 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 138 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 139 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 140 Europe Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 141 Germany Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR %)
  • Table 142 UK Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 143 France Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 144 Italy Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 145 Spain Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 146 Russia Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 147 Rest of Europe Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 148 Asia Pacific Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 149 Asia Pacific Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 150 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 151 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 152 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 153 Asia Pacific Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 154 Asia Pacific Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 155 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 156 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 157 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 158 Asia Pacific Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 159 Asia Pacific Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 160 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 161 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 162 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 163 Asia Pacific Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 164 Asia Pacific Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 165 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 166 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 167 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 168 Asia Pacific Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 169 Asia Pacific Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 170 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 171 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 172 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 173 Asia Pacific Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 174 Japan Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 175 China Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 176 India Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 177 Australia Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 178 South Korea Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 179 Rest of Asia Pacific Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 180 Latin America Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 181 Latin America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 182 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 183 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 184 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 185 Latin America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 186 Latin America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 187 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 188 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 189 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 190 Latin America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 191 Latin America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 192 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 193 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 194 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 195 Latin America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 196 Latin America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 197 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 198 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 199 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 200 Latin America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 201 Latin America Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 202 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 203 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 204 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 205 Latin America Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 206 Brazil Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 207 Mexico Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 208 Rest of Latin America Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 209 MEA Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 210 MEA Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 211 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 212 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 213 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 214 MEA Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 215 MEA Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 216 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 217 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 218 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 219 MEA Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 220 MEA Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 221 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 222 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 223 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 224 MEA Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 225 MEA Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 226 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 227 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 228 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 229 MEA Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 230 MEA Cellular Immunotherapy Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 231 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 232 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 233 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 234 MEA Cellular Immunotherapy Market Size Forecast by Indication, 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 235 South Africa Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 236 GCC Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 237 Rest of MEA Cellular Immunotherapy Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 238 Cellular Immunotherapy Market Recent Developments, 2018-2021
  • Table 239 Novartis AG: Key Details, (MD, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 240 Novartis AG: Product Benchmarking
  • Table 241 Novartis AG : Recent Developments, 2018-2021
  • Table 242 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 1 Kite Corporate (Gilead Sciences, Inc.): Product Benchmarking
  • Table 243 Kite Corporate (Gilead Sciences, Inc.) : Recent Developments, 2018-2021
  • Table 244 Adicet Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 245 Adicet Bio: Product Benchmarking
  • Table 246 Adicet Bio : Recent Developments, 2018-2021
  • Table 247 GlaxoSmithKline plc.: Key Details, (MD, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 248 GlaxoSmithKline plc: Product Benchmarking
  • Table 249 GlaxoSmithKline plc: Recent Developments, 2018-2021
  • Table 250 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 251 Pfizer Inc.: Product Benchmarking
  • Table 252 Pfizer Inc. : Recent Developments, 2018-2021
  • Table 253 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 254 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 255 F. Hoffmann-La Roche Ltd.: Recent Developments, 2018-2021
  • Table 256 Iovance Biotherapeutics, Inc.: Key Details, (CEO, HQ, Founded, No. of Employees, Company Type, Website)
  • Table 257 Iovance Biotherapeutics, Inc.: Product Benchmarking
  • Table 258 Iovance Biotherapeutics, Inc. : Recent Developments, 2018-2021
  • Table 259 Tessa Therapeutics Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 260 Tessa Therapeutics Ltd.: Product Benchmarking
  • Table 261 Tessa Therapeutics Ltd. : Recent Developments, 2018-2021
  • Table 262 Inovio Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 263 Inovio Pharmaceuticals, Inc.: Product Benchmarking
  • Table 264 Inovio Pharmaceuticals, Inc.: Recent Developments, 2018-2021
  • Table 265 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 266 AstraZeneca: Product Benchmarking
  • Table 267 AstraZeneca : Recent Developments, 2018-2021
  • Table 268 Adaptimmune Therapeutics plc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 269 Adaptimmune Therapeutics plc.: Product Benchmarking
  • Table 270 Atara Biotherapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 271 Atara Biotherapeutics, Inc.: Product Benchmarking
  • Table 272 Atara Biotherapeutics, Inc.: Recent Developments, 2018-2021
  • Table 273 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 274 Bristol-Myers Squibb Company: Product Benchmarking
  • Table 275 Bristol-Myers Squibb Company: Recent Developments, 2018-2021
  • Table 276 APAC Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 277 APAC Biotech: Product Benchmarking
  • Table 278 JW shinyak (JW CreaGene): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 279 JW shinyak (JW CreaGene): Product Benchmarking
  • Table 280 JW shinyak (JW CreaGene): Recent Developments, 2018-2021

List of Figures

  • Figure 1 Global Cellular Immunotherapy Market Size Forecast 2021-2031 (US$bn, AGR %)
  • Figure 2 Global Cellular Immunotherapy Market Segmentation
  • Figure 3 Global Cellular Immunotherapy Market: Market Trends
  • Figure 4 Global Cellular Immunotherapy Market: SWOT Analysis
  • Figure 5 Global Cellular Immunotherapy Market: Porter's Five Forces Analysis
  • Figure 6 Global Cellular Immunotherapy Market: PEST Analysis
  • Figure 7 Global Cellular Immunotherapy Market Size Forecast 2021-2031 (US$bn, AGR %)
  • Figure 8 Global Cellular Immunotherapy Market Size Forecast 2021-2031 (US$bn, AGR %): "V" Shaped Recovery
  • Figure 9 Global Cellular Immunotherapy Market Size Forecast 2021-2031 (US$bn, AGR %): "U" Shaped Recovery
  • Figure 10 Global Cellular Immunotherapy Market Size Forecast 2021-2031 (US$bn, AGR %): "W" Shaped Recovery
  • Figure 11 Global Cellular Immunotherapy Market Size Forecast 2021-2031 (US$bn, AGR %): "L" Shaped Recovery
  • Figure 12 Global CAR-T Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 13 "V" Shaped Recovery: Global CAR-T Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 14 "U" Shaped Recovery: Global CAR-T Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 15 "W" Shaped Recovery: Global CAR-T Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 16 "L" Shaped Recovery: Global CAR-T Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 17 Global NK Cell Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 18 "V" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 19 "U" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 20 "W" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 21 "L" Shaped Recovery: Global NK Cell Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 22 Global TIL Therapy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 23 "V" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 24 "U" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 25 "W" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 26 "L" Shaped Recovery: Global TIL Therapy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 27 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 28 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 29 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 30 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 31 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 32 Global Cellular Immunotherapy Market Share Forecast by Product and Services, 2021, 2026, 2031 (%)
  • Figure 33 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 34 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 35 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 36 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 37 Global Cellular Immunotherapy Market for Cellular Immunotherapy Product Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 38 Global Cellular Immunotherapy Market for Services Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 39 Global Cellular Immunotherapy Market for Services Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 40 Global Cellular Immunotherapy Market for Services Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 41 Global Cellular Immunotherapy Market for Services Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 42 Global Cellular Immunotherapy Market for Services Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 43 Global Cellular Immunotherapy Market Share Forecast by Testing Assays Type, 2021, 2026, 2031 (%)
  • Figure 44 Global Cellular Immunotherapy Market for Bioanalytics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 45 Global Cellular Immunotherapy Market for Bioanalytics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 46 Global Cellular Immunotherapy Market for Bioanalytics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 47 Global Cellular Immunotherapy Market for Bioanalytics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 48 Global Cellular Immunotherapy Market for Bioanalytics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 49 Global Cellular Immunotherapy Market for Characterization Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 50 Global Cellular Immunotherapy Market for Characterization Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 51 Global Cellular Immunotherapy Market for Characterization Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 52 Global Cellular Immunotherapy Market for Characterization Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 53 Global Cellular Immunotherapy Market for Characterization Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 54 Global Cellular Immunotherapy Market for Biosafety Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 55 Global Cellular Immunotherapy Market for Biosafety Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 56 Global Cellular Immunotherapy Market for Biosafety Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 57 Global Cellular Immunotherapy Market for Biosafety Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 58 Global Cellular Immunotherapy Market for Biosafety Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 59 Global Cellular Immunotherapy Market Share Forecast by Indication, 2021, 2026, 2031 (%)
  • Figure 60 Global B-cell Malignancies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 61 "V" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 62 "U" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 63 "W" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 64 "L" Shaped Recovery: Global B-cell Malignancies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 65 Global Prostate Cancer Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 66 "V" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 67 "U" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 68 "W" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 69 "L" Shaped Recovery: Global Prostate Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 70 Global Liver Cancer Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 71 "V" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 72 "U" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 73 "W" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 74 "L" Shaped Recovery: Global Liver Cancer Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 75 Global Renal Cell Carcinoma Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 76 "V" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 77 "U" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 78 "W" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 79 "L" Shaped Recovery: Global Renal Cell Carcinoma Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 80 Global Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 81 "V" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 82 "U" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 83 "W" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 84 "L" Shaped Recovery: Global Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 85 Global Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion): "V" Shaped Recovery
  • Figure 86 Global Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion): "U" Shaped Recovery
  • Figure 87 Global Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 88 Global Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 89 North America Cellular Immunotherapy Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 90 North America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 91 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 92 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 93 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 94 North America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 95 North America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 96 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 97 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 98 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 99 North America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 100 North America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 101 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 102 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 103 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 104 North America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 105 North America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 106 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 107 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 108 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 109 North America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 110 North America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 111 North America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 112 North America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 113 North America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 114 North America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 115 U.S. Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 116 Canada Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 117 Europe Cellular Immunotherapy Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 118 Europe Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 119 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 120 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 121 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 122 Europe Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 123 Europe Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 124 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 125 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 126 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 127 Europe Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 128 Europe Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 129 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 130 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 131 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 132 Europe Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 133 Europe Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 134 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 135 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 136 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 137 Europe Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 138 Europe Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 139 Europe Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 140 Europe Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 141 Europe Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 142 Europe Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 143 Germany Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 144 UK Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 145 France Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 146 Italy Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 147 Spain Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 148 Russia Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 149 Rest of Europe Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 150 Asia Pacific Cellular Immunotherapy Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 151 Asia Pacific Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 152 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 153 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 154 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 155 Asia Pacific Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 156 Asia Pacific Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 157 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 158 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 159 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 160 Asia Pacific Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 161 Asia Pacific Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 162 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 163 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 164 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 165 Asia Pacific Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 166 Asia Pacific Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 167 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 168 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 169 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 170 Asia Pacific Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 171 Asia Pacific Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 172 Asia Pacific Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 173 Asia Pacific Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 174 Asia Pacific Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 175 Asia Pacific Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 176 Japan Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 177 China Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 178 India Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 179 Australia Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 180 South Korea Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 181 Rest of Asia Pacific Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 182 Latin America Cellular Immunotherapy Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 183 Latin America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 184 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 185 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 186 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 187 Latin America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 188 Latin America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 189 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 190 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 191 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 192 Latin America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 193 Latin America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 194 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 195 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 196 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 197 Latin America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 198 Latin America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 199 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 200 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 201 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 202 Latin America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 203 Latin America Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 204 Latin America Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 205 Latin America Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 206 Latin America Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 207 Latin America Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 208 Brazil Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 209 Mexico Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 210 Rest of Latin America Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 211 MEA Cellular Immunotherapy Market Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 212 MEA Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 213 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 214 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 215 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 216 MEA Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 217 MEA Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 218 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 219 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 220 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 221 MEA Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 222 MEA Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 223 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 224 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 225 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 226 MEA Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 227 MEA Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 228 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 229 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 230 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 231 MEA Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 232 MEA Cellular Immunotherapy Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 233 MEA Cellular Immunotherapy Market Forecast by Therapy Type, 2021-2031 (US$ billion)
  • Figure 234 MEA Cellular Immunotherapy Market Forecast by Product & Service, 2021-2031 (US$ billion)
  • Figure 235 MEA Cellular Immunotherapy Market Forecast by Testing Assays Type, 2021-2031 (US$ billion)
  • Figure 236 MEA Cellular Immunotherapy Market Forecast by Indication, 2021-2031 (US$ billion)
  • Figure 237 South Africa Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 238 GCC Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 239 Rest of MEA Cellular Immunotherapy Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 240 Cellular Immunotherapy Market: Company Share Analysis, 2020
  • Figure 241 Novartis AG: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 242 Novartis AG: Business Segments Revenue Shares, 2020
  • Figure 243 Novartis AG: Pharmaceuticals Business Unit Revenue Shares, 2020
  • Figure 244 Novartis AG: Regional Revenue Shares, 2020
  • Figure 245 Gilead Sciences, Inc.: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 246 Gilead Sciences, Inc.: Business Segments Revenue Shares, 2020
  • Figure 247 Gilead Sciences, Inc.: Regional Revenue Shares, 2020
  • Figure 248 Adicet Bio: Net Revenue, 2016-2020 (US$ Million, AGR%)
  • Figure 249 GlaxoSmithKline plc.: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 250 GlaxoSmithKline plc.: Pharmaceutical Business Revenue Shares, 2020
  • Figure 251 GlaxoSmithKline plc.: Regional Revenue Shares, 2020
  • Figure 252 Pfizer Inc.: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 253 Pfizer Inc.: Product Segment Revenue Shares, 2020
  • Figure 254 Pfizer Inc.: Regional Segment Revenue Shares, 2020
  • Figure 255 F. Hoffmann-La Roche Ltd.: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 256 F. Hoffmann-La Roche Ltd.: Product Revenue Shares, 2020
  • Figure 257 F. Hoffmann-La Roche Ltd.: Regional Revenue Shares, 2020
  • Figure 258 Inovio Pharmaceuticals, Inc.: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 259 AstraZeneca: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 260 AstraZeneca: Product Revenue Shares, 2020
  • Figure 261 AstraZeneca: Regional Revenue Shares, 2020
  • Figure 262 Adaptimmune Therapeutics plc.: Net Revenue, 2016-2020 (US$ million, AGR%)
  • Figure 263 Bristol-Myers Squibb Company: Net Revenue, 2016-2020 (US$ billion, AGR%)
  • Figure 264 Bristol-Myers Squibb Company: Regional Revenue Shares, 2020
  • Figure 265 Global Cellular Immunotherapy Market Share Forecast by Therapy Type, 2021, 2026, 2031 (%)
  • Figure 266 Global Cellular Immunotherapy Market Share Forecast by Region, 2021, 2026, 2031 (%)

Companies Profiled in the Report:

  • Adaptimmune Therapeutics plc.
  • Adicet Bio
  • APAC Biotech
  • AstraZeneca
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • JW Shinyak (JW CreaGene)
  • Novartis AG
  • Pfizer Inc.
  • Tessa Therapeutics Ltd.

List of Companies Mentioned in the Report:

  • Abingworth
  • Acorn Campus Ventures
  • Adaptimmune
  • AFA FÖrsäkring
  • AGF Private Equity
  • AgonOx
  • Agreen Biotech
  • Aju IB Investment
  • Alaska Permanent Fund
  • Alexandria Ventures
  • Allos Therapeutics
  • Altor BioScience
  • Amgen
  • Applied Immune Technologies
  • Aquilo Capital Management
  • ARCH Venture Partners
  • Artax Biopharma
  • AstraZeneca
  • Atara Biotherapeutics
  • Atlas Venture
  • Autolus (spin off from UCL)
  • AVG Ventures
  • Banca Esperia
  • BankInvest Biomedical Venture
  • Bayer
  • Baylor College of Medicine
  • Bellicum Pharmaceuticals
  • Bezos Expeditions
  • Biogen
  • BioNTech
  • Biotecnol
  • bluebird bio
  • Bpifrance
  • Brace Pharma Capital
  • Bristol-Myers Squibb
  • Broad Institute
  • Broadfin Capital
  • Cabaret Biotech
  • California Institute for Regenerative Medicine
  • California Institute of Technology
  • California Stem Cell Agency
  • Cancer Prevention and Research Institute of Texas
  • Caribou Sciences
  • CARsgen
  • Casdin Capital
  • Catalyst
  • Celdara
  • Celgene
  • Cell Therapy Catapult
  • Cellectis
  • CELLforCURE
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Celyad
  • Children with Leukaemia
  • Chinese PLA General Hospital
  • City of Hope Medical Center
  • CLL Global Research Foundation Alliance
  • Cold Genesys
  • Conkwest
  • Cowen Investment
  • CRISPR Therapeutics
  • CrunchFund
  • Cyto Pulse
  • Dartmouth College
  • Deerfield Partners
  • Dendreon Corporation
  • Deutsche Krebshilfe
  • Duke University
  • Easton Capital
  • EcoR1 Capital
  • Editas Medicine
  • Edmond Venture Capital
  • Ehime University
  • Eisai
  • Eli Lilly
  • Endocyte
  • Erasmus University
  • Eureka Therapeutics
  • Fate Therapeutics
  • Felicis Ventures
  • Fidelity Biosciences
  • Fiverings Co.
  • Flagship Ventures
  • Forbion Capital Partners
  • Foresite Capital
  • Formula Pharmaceuticals
  • Fred Hutchinson Cancer Research Center
  • Fujita Health University
  • GammaCell Biotechnologies
  • Genentech
  • Genzyme (Sanofi)
  • Genzyme Ventures
  • Gilead Sciences
  • GlaxoSmithKline
  • Google Ventures
  • Griffin Securities
  • H. Lee Moffitt Cancer Center and Research Institute
  • Harbinger Venture Capital
  • Harvard University
  • Healthcare investment company Syncona
  • Heat Biologics
  • Herlev Hospital
  • High Line Venture Partners
  • ImmunoCellular Therapeutics
  • Immunocore
  • Imperial Innovations
  • IMS Health Capital
  • Innovative Genome Initiative
  • Intellia Therapeutics
  • Intrexon
  • Iowa State University
  • Jannsen Biotech
  • Jennison Associates
  • Jichi Medical University
  • JMP Securities
  • John Hopkins University
  • John Wayne Cancer Institute
  • Jonsson Comprehensive Cancer Center
  • JP Moulton Charitable Foundation
  • Juno Therapeutics
  • Karolinska University Hospital
  • Keio University, School of Medicine
  • Khosla Ventures
  • Kite Pharma
  • Leiden University Medical Center
  • Leukemia and Lymphoma Society
  • Ligand Pharmaceuticals
  • Lion Biotechnologies
  • Lonza Biologics
  • Loyola University
  • M.D. Anderson Cancer Center
  • Massachusetts Institute of Technology
  • MaxCyte
  • Mayo Clinic
  • Medigene
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merck Serono
  • Mie University
  • Millennium Pharmaceuticals
  • MolMed
  • Monash University
  • Morphotek
  • Mustang Therapeutics
  • Nagoya University
  • Nantes University Hospital
  • Nantworks
  • National Cancer Institute
  • National Institute of Health
  • National University of Singapore
  • NeoStem
  • New Enterprise Associates (NEA)
  • New Leaf Venture
  • Novartis
  • Novartis Institute for Biomedical Research (NIBR)
  • Novo A/S
  • Oberland Capital Healthcare
  • ODYSSEE Venture
  • Ohio University
  • Omega Funds
  • Oncodesign Biotechnology
  • OnCyte
  • Ono Pharmaceutical Co.
  • Onyx Pharmaceuticals
  • Opexa Therapeutics
  • Opus Bio
  • OrbiMed Advisors
  • Oxford BioMedica
  • Partners Innovation Fund
  • Pasteur Institute
  • Peking University
  • Perceptive Advisors
  • Perelman School of Medicine, University of Pennsylvania
  • Peter MacCallum Cancer Centre, University of Melbourne
  • Pfizer
  • Pharmacyclics
  • Polaris Partners
  • Pontifax
  • Precision Biosciences/Pregenen
  • Precision Genome Engineering
  • Progenitor Cell Therapy
  • Pure MHC
  • QueensBridge Venture Partners
  • Quogue Capital
  • QVT Financial
  • RA capital Management
  • Ramius Capital Group
  • Redmile Group
  • Remeditex Ventures
  • Renji Hospital
  • Ridgeway Capital Partners
  • Riverbank Capital Securities
  • Roche
  • Rock Spring Capital
  • Roswell Park Cancer Institute
  • Sabby Capital
  • San Raffaele Hospital (OSR)
  • Sanderling Ventures
  • Sangamo Biosciences
  • Sanofi-Genzyme BioVentures
  • Seattle Children's Hospital
  • Seattle Genetics
  • Sectoral Asset Management
  • Servier
  • Shanghai Cancer Institute
  • Sheba Medical Center
  • Shenzhen Second People's Hospital
  • Shionogi
  • Silicon Valley Bank
  • Sorrento Therapeutics
  • Southwest Hospital
  • Spectrum Pharmaceuticals
  • SR One
  • St. Jude Children's Research Hospital
  • Stage Cell Therapeutics
  • Statcom Co.
  • Suma Ventures
  • Sun Yat-Sen University
  • Sunol Molecular Corporation
  • SV Angel
  • Swedish Cancer Society
  • T-Cell Factory
  • T. Rowe Price Associates
  • Takara Bio
  • Tel Aviv Sourasky Medical Centre
  • TETHYS
  • Texas Children's Hospital
  • The Children's Hospital of Philadelphia
  • The Christie NHS Foundation Trust
  • The Methodist Hospital System
  • The Netherlands Cancer Institute
  • Theravectys
  • Thermo Fisher Scientific
  • Third Rock Ventures
  • Three Arch Opportunity Fund
  • TILT Biotherapeutics
  • TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
  • Transposagen Biopharmaceuticals
  • TVM Capital
  • Two Blades Foundation
  • TxCell
  • University College of London
  • University Health Network
  • University of California
  • University of Connecticut
  • University of Florida
  • University of Milano-Bicocca
  • University of Minnesota
  • University of Oxford
  • University of Southern California
  • University of Zurich
  • Unum Therapeutics
  • Uppsala University
  • Valeant Pharmaceuticals
  • venBio
  • Venrock
  • Versant Ventures
  • Viking Global Investors
  • Weill Cornell Medical College
  • Weizmann Institute of Science
  • Wellington Management
  • X-Body
  • Y Combinator
  • Yuan Capital
  • ZIOPHARM Oncology

List of Organizations Mentioned in the Report:

  • ACRF Centre for Advanced Cellular Immunotherapy
  • Agencia Nacional de Vigiloncia Sanitaria (ANVISA)
  • American Cancer Society (ACS)
  • Center for Biologics Evaluation and Research (CBER)
  • Center for Devices and Radiological Health (CDRH)
  • Center of Excellence in Immunology (CEI)
  • Centers for Disease Control and Prevention (CDC)
  • Centers for Medicare & Medicaid Services programs
  • European Medicines Agency (EMA)
  • European Union
  • Experimental Transplantation & Immunotherapy Branch at CCR
  • Food and Drug Administration (FDA)
  • French Government
  • Government of Japan
  • Health Ministry (Italy)
  • Indian Council of Medical Research (ICMR)
  • Institute for Healthcare Improvement (IHI)
  • International Agency for Research on Cancer (IARC)
  • Italian Industry Group Farmindustria
  • Japanese Ministry of Health, Labour and Welfare
  • Laboratory of Tumor Immunology and Biology at CCR
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Health, Labour & Welfare (MHLW)
  • National Cancer Institute (NCI)
  • National Cancer Institute's Center for Cancer Research (CCR)
  • National Development and Reform Commission (NDRC)
  • National Institutes of Health (NIH)
  • NCBI
  • NCI's Division of Cancer Biology's Cancer Immunology, Hematology, and Etiology Branch (CIHEB)
  • The Therapeutic Goods Administration
  • United Nations (UN)
  • University of Connecticut
  • World Health Organization (WHO)
  • World Population Prospects